StockData

CorMedix vs Organogenesis

CRMD and ORGO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRMD and ORGO compare

CorMedix is the larger company, worth 3.5 times as much as Organogenesis ($364M against $104M).

CorMedix grew revenue faster over the last twelve months (281% versus 6.5% for Organogenesis).

CorMedix keeps more of each dollar of sales as profit, with a net margin of 40.5% compared with −18.4% at Organogenesis.

CorMedix scores higher on the StockData Score (13 against 10 for Organogenesis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRMDORGO
Size and price
Market cap$364M$104M
Share price$4.67$0.812
Change, 1 year−58.5%−86.7%
Change, 5 years−7.9%−91.8%
Beta (5Y)0.490.57
Employees191854
StockData Score
Total score13 (better)10
Valuation score11
Growth score3 (better)1
Performance score4 (better)3
Health score55
Dividend score00
Valuation
P/S0.8×0.2× (better)
P/B0.8×0.7× (better)
EV/EBITDA0.5×–
P/FCF1.5× (better)5.0×
FCF yield68.8% (better)20.0%
Growth
Revenue growth (TTM)281% (better)6.5%
Revenue growth, 5Y average320% (better)10.8%
Net income growth (TTM)266%–
EPS growth, 5Y average–0.00%
Profitability
Gross margin82.8%–
Operating margin47.0% (better)−7.8%
Net margin40.5% (better)−18.4%
FCF margin54.2% (better)4.6%
Return on equity54.9% (better)−44.1%
Return on invested capital171% (better)−21.7%
Financial health
Debt / equity0.000.00
Current ratio2.563.52 (better)
Altman Z-score2.01 (better)1.26
Piotroski F-score55
Dividends and buybacks
Buyback yield−0.28%–
Shareholder yield−0.28%0.00% (better)
Ownership
Held by institutions56.5%53.2%
Held by insiders3.3%–
Insider net buying, 12 months−$1.6M−$988K (better)
Short interest, % of float18.8%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.